Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy.

McGurk, Kathryn A; Bilgehan, Nagme; Ware, James S

McGurk, Kathryn A; Bilgehan, Nagme; Ware, James S.

Affiliation

McGurk KA; National Heart and Lung Institute and MRC Laboratory of Medical Sciences, Imperial College London, UK (K.A.M., N.B., J.S.W.).
Bilgehan N; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA (K.A.M., J.S.W.).
Ware JS; National Heart and Lung Institute and MRC Laboratory of Medical Sciences, Imperial College London, UK (K.A.M., N.B., J.S.W.).

Circulation ; 149(23): 1786-1788, 2024 Jun 04.

Article de En | MEDLINE | ID: mdl-38829931

Sujet(s)
Mots clés

MYK-461; cardiomyopathy, hypertrophic; pharmacogenetics

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Pharmacogénétique / Cardiomyopathie hypertrophique Limites: Humans Langue: En Journal: Circulation Année: 2024 Type de document: Article

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google